Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600X |
| Therapy | Binimetinib + Encorafenib |
| Indication/Tumor Type | melanoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600X | melanoma | predicted - sensitive | Binimetinib + Encorafenib | Clinical Study | Actionable | In a retrospective analysis, real-world treatment with the combination of Mektovi (binimetinib) and Braftovi (encorafenib) demonstrated activity in melanoma patients with brain metastases harboring a BRAF V600 mutation, with an objective response rate of 69.4% (125/180, 4 complete and 121 partial responses), median progression-free survival of 5.5 months, and median overall survival of 11.9 months (PMID: 40411977). | 40411977 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40411977) | Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry. | Full reference... |